Home
Live Updates
Agios sells vorasidenib royalty rights to Royalty Pharma for $905M : comparemela.com
Agios sells vorasidenib royalty rights to Royalty Pharma for $905M
Vorasidenib, which treats IDH-mutant diffuse glioma, showed efficacy in data released last year.
Related Keywords
Brian Goff ,
Pablo Legorreta ,
Drug Administration ,
Agios Pharmaceuticals ,
Royalty Pharma ,
Prescription Drug User Fee Act ,
comparemela.com © 2020. All Rights Reserved.